Fair Money & Economic Opportunity

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of drug candidates.

Its core business activities, as described in the provided articles, do not involve offering lending, deposit services, or other financial products to consumers. Therefore, all Key Performance Indicators related to 'Fair Money & Economic Opportunity', such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial products, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for financial services, and product simplicity for financial products, are not applicable to the company's operations. No evidence was found in the articles to score any of these KPIs.

Fair Pay & Worker Respect

Employee reviews from Indeed.com indicate an overall employee satisfaction rating of 4.0 out of 5 stars.

This is supported by specific ratings of 4.5 out of 5 for work-life balance and culture on Indeed, and 4.2 out of 5 for culture and values, work-life balance, and senior management on Glassdoor. Employees describe a relaxed, positive, and diverse atmosphere with opportunities for growth and flexible work schedules. Several staff members have also been with the company for multiple years.

Honest & Fair Business

No information could be extracted from the provided articles. All articles were error messages indicating that the request was auto-throttled, and therefore contained no factual data relevant to VTVT.US or the 'Honest & Fair Business' value.

As a result, no KPIs could be scored.

Kind to Animals

The company relies on animal models for drug development, with HPP737 showing therapeutic activity in several animal models of inflammation, and preclinical testing for cadisegliatin involving animal studies.

There is no evidence of the use of non-animal testing methods. Preclinical testing, including animal studies, is performed in accordance with FDA's good laboratory practice (GLP) regulations and standards. Long-term preclinical testing, such as animal tests for reproductive adverse events, carcinogenicity, and long-term toxicity studies, may continue after an Investigational New Drug (IND) application is submitted. Carcinogenicity studies were completed in 2024. The company uses 25,000–50,000 animals annually across major product lines, as implied by the use of 'several animal models' for multiple drug candidates without any stated reduction targets or specific numbers.

No War, No Weapons

The provided articles for vTv Therapeutics Inc. focus on SEC filings, licensing agreements, and executive appointments.

None of the articles contain specific, factual information or data points regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other defense-related activities. Therefore, no KPIs under the 'No War, No Weapons' value can be scored based on the available evidence.

Safe & Smart Tech

vTv Therapeutics Inc. has reported no material cybersecurity incidents to date and no incidents of unauthorized data use.

The company utilizes third-party vendors for penetration testing and audits, indicating standard vulnerability management and security testing practices. Additionally, the company is noted to be in compliance with FDA regulations concerning patient information.